Market Research Logo

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview
Therapeutics Development
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
AnGes MG, Inc.
AstraZeneca PLC
Bayer AG
Biosidus S.A.
Biscayne Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Cardiome Pharma Corp
CardioVascular BioTherapeutics, Inc.
Eagle Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Hemostemix Ltd
Human Stem Cells Institute
Isis Pharmaceuticals, Inc.
Juventas Therapeutics, Inc.
Lacer, S.A.
Lee's Pharmaceutical Holdings Limited
Lonestar Heart, Inc.
MedImmune, LLC
Merck & Co., Inc.
Miltenyi Biotec GmbH
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Regado Biosciences, Inc.
The Medicines Company
ViroMed Co., Ltd.
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptamers for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biglycan Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIS-5409 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bivalirudin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bivalirudin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BQ-123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C2 ceramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C6 ceramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cangrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cryocell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemacell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate VEGF for Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-APOARx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-CRPRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-6012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiGeneGraft - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MZ-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins for Ischemic Heart Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Coronary Artery Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Modulate CD36 Receptor for Ischemic Heart Disease and Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tirofiban hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XL-652 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago
Oct 27, 2014: The Medicines Company Wins Favorable Judgment in Angiomax (Bivalirudin) Patent Litigation
Oct 06, 2014: Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APO(A)RX At European Society of Cardiology Congress 2014
Jul 07, 2014: The Medicines Company Receives Market Authorization Renewal for Angiox (Bivalirudin) from the European Medicines Agency and the European Commission
Apr 28, 2014: The Medicines Company Files Petition Against Aurobindo Over Patent Infringement
Mar 30, 2014: Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax Presented at ACC.14
Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor
Oct 11, 2013: Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT
Oct 09, 2013: First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax in Patients Undergoing Peripheral Endovascular Procedures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Regado Biosciences, Inc., H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H1 2015
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report